{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:11:16Z","timestamp":1787987476072,"version":"build-2784847793"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011723","name":"Myeloma UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007903","name":"Bloodwise","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000769","name":"University of Oxford","doi-asserted-by":"publisher","award":["Crankstart Bursary"],"award-info":[{"award-number":["Crankstart Bursary"]}],"id":[{"id":"10.13039\/501100000769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Early Career Award (227000\/Z\/23\/Z)"],"award-info":[{"award-number":["Early Career Award (227000\/Z\/23\/Z)"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"name":"M.F. Kaiser is supported by a fellowship from the David Forbes-Nixon Foundation."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Although treatment options for B-cell malignancies have expanded, many patients continue to face limited response rates, highlighting an urgent need for new therapeutic targets. To prioritize candidate drug targets for B-cell malignancies, we employed Mendelian Randomization to estimate potentially causal relationships between 445 immune cell traits and six B-cell cancers: follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL), marginal zone lymphoma (MZL), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM), totaling 22,922 cases and 394,204 controls. 163 traits showed a suggestive association with at least one B-cell malignancy (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05), with 34 traits being significant after correction for multiple testing (<jats:italic>P<\/jats:italic>\u2009&lt;\u20092\u2009\u00d7\u200910<jats:sup>\u22124<\/jats:sup>). By integrating findings with observational data and clinical trial evidence to support drug target candidacy, 24 cell surface markers were identified as druggable targets. In addition to established therapeutic targets such as CD3, CD20 and CD38, our analysis highlights BAFF-R and CD39 in HL, CD25 in MM, CD27 in CLL, CD80\/86 in DLBCL, and CCR2 in FL and MZL as promising candidates for therapeutic inhibition. Our findings provide further support for the potential of human genetics to guide the identification of drug targets and address a productivity-limiting step.<\/jats:p>","DOI":"10.1038\/s41408-025-01277-x","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T01:46:46Z","timestamp":1744163206000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Mendelian randomization of immune cell phenotypes to discover potential drug targets for B-cell malignancy"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0609-2644","authenticated-orcid":false,"given":"Sina A.","family":"Beer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3271-975X","authenticated-orcid":false,"given":"Molly","family":"Went","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4755-7549","authenticated-orcid":false,"given":"Charlie","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Codie","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6133-0164","authenticated-orcid":false,"given":"Amit","family":"Sud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7580-5087","authenticated-orcid":false,"given":"James M.","family":"Allan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5268-0242","authenticated-orcid":false,"given":"Richard","family":"Houlston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3677-4804","authenticated-orcid":false,"given":"Martin F.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"1277_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.18632\/oncoscience.583","volume":"10","author":"E Izbicka","year":"2023","unstructured":"Izbicka E, Streeper RT. Cancer drug development yesterday, today and tomorrow. Oncoscience. 2023;10:32\u20133.","journal-title":"Oncoscience"},{"key":"1277_CR2","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41375-023-01852-w","volume":"37","author":"K Hemminki","year":"2023","unstructured":"Hemminki K, Hemminki J, F\u00f6rsti A, Sud A. Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment. Leukemia. 2023;37:854\u201363.","journal-title":"Leukemia"},{"key":"1277_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00970-z","volume":"14","author":"ERA Pennings","year":"2024","unstructured":"Pennings ERA, Durmaz M, Visser O, Posthuma EFM, Issa DE, Chamuleau MED, et al. Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands. Blood Cancer J. 2024;14:3.","journal-title":"Blood Cancer J"},{"key":"1277_CR4","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/bjh.18654","volume":"200","author":"D Minakata","year":"2023","unstructured":"Minakata D, Fujiwara SI, Yokoyama D, Noguchi A, Aoe S, Oyama T, et al. Relapsed and refractory multiple myeloma: a systematic review and network meta-analysis of the efficacy of novel therapies. Br J Haematol. 2023;200:694\u2013703.","journal-title":"Br J Haematol"},{"key":"1277_CR5","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","volume":"21","author":"KJ Hiam-Galvez","year":"2021","unstructured":"Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer. 2021;21:345\u201359.","journal-title":"Nat Rev Cancer"},{"key":"1277_CR6","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1038\/s41588-024-01854-z","volume":"56","author":"O Razuvayevskaya","year":"2024","unstructured":"Razuvayevskaya O, Lopez I, Dunham I, Ochoa D. Genetic factors associated with reasons for clinical trial stoppage. Nat Genet. 2024;56:1862\u20137.","journal-title":"Nat Genet"},{"key":"1277_CR7","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/ng.2982","volume":"46","author":"SY Shin","year":"2014","unstructured":"Shin SY, Fauman EB, Petersen AK, Krumsiek J, Santos R, Huang J, et al. An atlas of genetic influences on human blood metabolites. Nat Genet. 2014;46:543\u201350.","journal-title":"Nat Genet"},{"key":"1277_CR8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.cell.2013.08.041","volume":"155","author":"V Orr\u00f9","year":"2013","unstructured":"Orr\u00f9 V, Steri M, Sole G, Sidore C, Virdis F, Dei M, et al. Genetic variants regulating immune cell levels in health and disease. Cell. 2013;155:242\u201356.","journal-title":"Cell"},{"key":"1277_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s43586-021-00092-5","volume":"2","author":"E Sanderson","year":"2022","unstructured":"Sanderson E, Glymour MM, Holmes MV, Kang H, Morrison J, Munaf\u00f2 MR, et al. Mendelian randomization. Nat Rev Methods Prim. 2022;2:6.","journal-title":"Nat Rev Methods Prim"},{"key":"1277_CR10","doi-asserted-by":"publisher","first-page":"n2233","DOI":"10.1136\/bmj.n2233","volume":"375","author":"VW Skrivankova","year":"2021","unstructured":"Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, VanderWeele TJ, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. Bmj. 2021;375:n2233. VolPages","journal-title":"Bmj"},{"key":"1277_CR11","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41588-020-0684-4","volume":"52","author":"V Orr\u00f9","year":"2020","unstructured":"Orr\u00f9 V, Steri M, Sidore C, Marongiu M, Serra V, Olla S, et al. Complex genetic signatures in immune cells underlie autoimmunity and inform therapy. Nat Genet. 2020;52:1036\u201345.","journal-title":"Nat Genet"},{"key":"1277_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10933","volume":"7","author":"SI Berndt","year":"2016","unstructured":"Berndt SI, Camp NJ, Skibola CF, Vijai J, Wang Z, Gu J, et al. Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. Nat Commun. 2016;7:10933.","journal-title":"Nat Commun"},{"key":"1277_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6751","volume":"6","author":"J Vijai","year":"2015","unstructured":"Vijai J, Wang Z, Berndt SI, Skibola CF, Slager SL, de Sanjose S, et al. A genome-wide association study of marginal zone lymphoma shows association to the HLA region. Nat Commun. 2015;6:5751.","journal-title":"Nat Commun"},{"key":"1277_CR14","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/ng.3105","volume":"46","author":"JR Cerhan","year":"2014","unstructured":"Cerhan JR, Berndt SI, Vijai J, Ghesqui\u00e8res H, McKay J, Wang SS, et al. Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nat Genet. 2014;46:1233\u20138.","journal-title":"Nat Genet"},{"key":"1277_CR15","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.ajhg.2014.09.004","volume":"95","author":"CF Skibola","year":"2014","unstructured":"Skibola CF, Berndt SI, Vijai J, Conde L, Wang Z, Yeager M, et al. Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. Am J Hum Genet. 2014;95:462\u201371.","journal-title":"Am J Hum Genet"},{"key":"1277_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/ng.2843","volume":"46","author":"HE Speedy","year":"2014","unstructured":"Speedy HE, Di Bernardo MC, Sava GP, Dyer MJ, Holroyd A, Wang Y, et al. A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. Nat Genet. 2014;46:56\u201360.","journal-title":"Nat Genet"},{"key":"1277_CR17","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/ng.219","volume":"40","author":"MC Di Bernardo","year":"2008","unstructured":"Di Bernardo MC, Crowther-Swanepoel D, Broderick P, Webb E, Sellick G, Wild R, et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet. 2008;40:1204\u201310.","journal-title":"Nat Genet"},{"key":"1277_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00320-1","volume":"8","author":"A Sud","year":"2017","unstructured":"Sud A, Thomsen H, Law PJ, F\u00f6rsti A, Filho MIdS, Holroyd A, et al. Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility. Nat Commun. 2017;8:1892.","journal-title":"Nat Commun"},{"key":"1277_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50932-7","volume":"15","author":"M Went","year":"2024","unstructured":"Went M, Duran-Lozano L, Halldorsson GH, Gunnell A, Ugidos-Damboriena N, Law P, et al. Deciphering the genetics and mechanisms of predisposition to multiple myeloma. Nat Commun. 2024;15:6644.","journal-title":"Nat Commun"},{"key":"1277_CR20","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/ije\/dyt179","volume":"42","author":"M-JA Brion","year":"2012","unstructured":"Brion M-JA, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. Int J Epidemiol. 2012;42:1497\u2013501.","journal-title":"Int J Epidemiol"},{"key":"1277_CR21","doi-asserted-by":"publisher","first-page":"D1311","DOI":"10.1093\/nar\/gkaa840","volume":"49","author":"M Ghoussaini","year":"2021","unstructured":"Ghoussaini M, Mountjoy E, Carmona M, Peat G, Schmidt EM, Hercules A, et al. Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics. Nucleic Acids Res. 2021;49:D1311\u2013d20.","journal-title":"Nucleic Acids Res"},{"key":"1277_CR22","doi-asserted-by":"publisher","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","volume":"52","author":"C Knox","year":"2024","unstructured":"Knox C, Wilson M, Klinger CM, Franklin M, Oler E, Wilson A, et al. DrugBank 6.0: the DrugBank Knowledgebase for 2024. Nucleic Acids Res. 2024;52:D1265\u2013d75.","journal-title":"Nucleic Acids Res"},{"key":"1277_CR23","unstructured":"Medicine. NLo. ClinicalTrials.gov. n.d."},{"key":"1277_CR24","doi-asserted-by":"crossref","unstructured":"Hemani G, Zheng, J, Elsworth, B, Wade, K, Haberland, V, Baird, D, et al. The MR-Base platform supports systematic causal inference across the human phenome. eLife. 2018;7:e34408.","DOI":"10.7554\/eLife.34408"},{"key":"1277_CR25","doi-asserted-by":"crossref","unstructured":"Zheng J, Richardson TG, Millard LAC, Hemani G, Elsworth BL, Raistrick CA, et al. PhenoSpD: an integrated toolkit for phenotypic correlation estimation and multiple testing correction using GWAS summary statistics. Gigascience. 2018;7:giy090.","DOI":"10.1093\/gigascience\/giy090"},{"key":"1277_CR26","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/ncprheum0624","volume":"3","author":"X Valencia","year":"2007","unstructured":"Valencia X, Lipsky PE. CD4+CD25+FoxP3+ regulatory T cells in autoimmune diseases. Nat Clin Pr Rheumatol. 2007;3:619\u201326.","journal-title":"Nat Clin Pr Rheumatol"},{"key":"1277_CR27","doi-asserted-by":"crossref","unstructured":"Mulder TA, Wahlin BE, \u00d6sterborg A, Palma M. Targeting the immune microenvironment in lymphomas of b-cell origin: from biology to clinical application. Cancers. 2019;11:915.","DOI":"10.3390\/cancers11070915"},{"key":"1277_CR28","first-page":"1","volume":"2","author":"B Kinnersley","year":"2018","unstructured":"Kinnersley B, Sud A, Coker EA, Tym JE, Di Micco P, Al-Lazikani B, et al. Leveraging human genetics to guide cancer drug development. JCO Clin Cancer Inf. 2018;2:1\u201311.","journal-title":"JCO Clin Cancer Inf"},{"key":"1277_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000629","volume":"4","author":"AM Starzer","year":"2020","unstructured":"Starzer AM, Berghoff AS. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open. 2020;4:e000629.","journal-title":"ESMO Open"},{"key":"1277_CR30","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s00280-019-03796-4","volume":"83","author":"C Massard","year":"2019","unstructured":"Massard C, Soria JC, Krauss J, Gordon M, Lockhart AC, Rasmussen E, et al. First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed\/refractory renal cell carcinoma. Cancer Chemother Pharm. 2019;83:1057\u201363.","journal-title":"Cancer Chemother Pharm"},{"key":"1277_CR31","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.autrev.2018.12.008","volume":"18","author":"R Felten","year":"2019","unstructured":"Felten R, Scher F, Sibilia J, Gottenberg JE, Arnaud L. The pipeline of targeted therapies under clinical development for primary Sj\u00f6gren\u2019s syndrome: a systematic review of trials. Autoimmun Rev. 2019;18:576\u201382.","journal-title":"Autoimmun Rev"},{"key":"1277_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00500-w","volume":"11","author":"Y Liu","year":"2023","unstructured":"Liu Y, Li Z, Zhao X, Xiao J, Bi J, Li XY, et al. Review immune response of targeting CD39 in cancer. Biomark Res. 2023;11:63.","journal-title":"Biomark Res"},{"key":"1277_CR33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KTH, Guan X-Y. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther. 2024;9:175.","journal-title":"Signal Transduct Target Ther"},{"key":"1277_CR34","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.cpt.2022.12.002","volume":"1","author":"H Ahmed","year":"2023","unstructured":"Ahmed H, Mahmud AR, Siddiquee MF, Shahriar A, Biswas P, Shimul MEK, et al. Role of T cells in cancer immunotherapy: opportunities and challenges. Cancer Pathog Ther. 2023;1:116\u201326.","journal-title":"Cancer Pathog Ther"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01277-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01277-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01277-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T01:46:49Z","timestamp":1744163209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01277-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1277"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01277-x","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"28 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The analysis was undertaken using published GWAS data, hence ethical approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"62"}}